Trial Information
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-Of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)
Sponsor: Celcuity Inc. PSI-CRO
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
